Flexion Therapeutics Announces Preliminary First-Quarter 2021 Revenue and Provides Financial Guidance for 2021
13. April 2021 16:01 ET
|
Flexion Therapeutics, Inc.
First-quarter ZILRETTA® net sales estimated to be approximately $24.6 million2021 full-year ZILRETTA net sales anticipated to be in the range of $120 million to $130 million and total operating...
Flexion Therapeutics to Present at the Needham 20th Annual Virtual Healthcare Conference
08. April 2021 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02. April 2021 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 60,880 restricted stock...
Flexion Therapeutics Announces First Patient Treated in FX301 Phase 1b Trial for Management of Post-Operative Pain
31. März 2021 07:30 ET
|
Flexion Therapeutics, Inc.
FX301 is a locally administered NaV1.7 inhibitor (funapide) formulated for extended release in a proprietary thermosensitive hydrogelProof-of-concept trial will evaluate safety and tolerability of...
Flexion Therapeutics to Present at the Oppenheimer 31st Annual Virtual Healthcare Conference
15. März 2021 09:00 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial Results
10. März 2021 16:01 ET
|
Flexion Therapeutics, Inc.
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $85.6 million for full-year 2020 representing 17% growth over 2019First patient treated in high...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05. März 2021 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of 14,565 restricted stock...
Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2020 Financial Results on March 10, 2021
03. März 2021 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2020 financial results after the...
Flexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301, a Novel Formulation of a Locally Administered NaV1.7 Inhibitor for Post-Operative Pain
01. März 2021 07:30 ET
|
Flexion Therapeutics, Inc.
FX301 combines NaV1.7 inhibitor (funapide) with a proprietary thermosensitive hydrogel to facilitate administration as a peripheral analgesic nerve blockFX301 may provide 3 to 5 days of non-opioid...
Flexion Therapeutics to Present at the 42nd Annual Raymond James Virtual Institutional Investors Conference
22. Februar 2021 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...